Girls n = 37 | Boys n = 16 | p-value1 | |
---|---|---|---|
Age at study visit, years Md (range) | 14 (8–18) | 14 (10–18) | 0.612 |
CHAQ Disability Index2, n (%) | |||
No-mild | 12 (32) | 5 (31) | 0.841 |
Mild- moderate | 9 (24) | 5 (31) | |
Moderate | 12 (32) | 6 (37) | |
Severe | 3 (8) | ||
Missing | 1 (3) | ||
Pain VAS3, 0–100 Md (range) | 31 (0–93) | 51 (0–99) | 0.377 |
Well-being VAS4, 0–100 Md (range) | 21 (0–99) | 28 (0–100) | 0.488 |
School absence days5, Md (range) | 0 (0–14) | 0 (0–6) | 0.258 |
Physical education attendance, n (%) | |||
Always | 12 (32) | 9 (56) | 0.105 |
Sometimes | 15 (41) | 5 (31) | |
Not at all | 6 (16) | 2 (12) | |
Not relevant | 3 (8) | ||
Missing | 1 (3) | ||
Disease duration, years Md (range) | 5 (0–16) | 2 (0–13) | 0.054 |
ESR6, mm/hour Md (range) | 5 (2–31) | 4 (2–35) | 0.175 |
Disease activity categories, n (%) | |||
No | 12 (32) | 9 (56) | 0.221 |
Low | 20 (54) | 5 (31) | |
Moderate | 4 (11) | 2 (12) | |
High | 0 | 0 | |
Missing | 1 (3) | ||
Use of medications7, n (%) | |||
DMARD | 24 (65%) | 7 (44%) | 0.704 |
NSAID | 25 (68%) | 8 (50%) | 0.416 |
Biologic medication | 4 (11%) | 0 | |
Corticosteroid therapy | 7 (19%) | 0 |